109.12MMarket Cap
LossP/E TTM
Key Figures
4.620Open
4.720High
106.47KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.44%Turnover Ratio
4.670Prev. Close
4.380Low
399.64KTurnover
LossP/E Static
7.56P/B
0.00%Div Yield TTM
-43.72%ROA
12.23052wk High
0.61Volume Ratio
-15.12MNet Profit
24.09MShares
-0.8896EPS TTM
1.99Beta
-193.58%ROE
2.59052wk Low
7.28%Amplitude
58.97%Gross Margin
109.12MMarket Cap
1.55Reward/Risk
3.96%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Exagen Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 34 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.57.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Exagen Inc Highlights
StrengthsRisks
Exagen Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Exagen Inc Info
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Ticker SymbolXGN
CompanyExagen Inc
CEOAballi (John)
Websitehttps://exagen.com/
Shareholders
FAQs
What is the current price of Exagen Inc (XGN)?
The current price of Exagen Inc (XGN) is 4.53.
What is the symbol of Exagen Inc?
The ticker symbol of Exagen Inc is XGN.
What is the 52-week high of Exagen Inc?
The 52-week high of Exagen Inc is 12.23.
What is the 52-week low of Exagen Inc?
The 52-week low of Exagen Inc is 2.59.
What is the market capitalization of Exagen Inc?
The market capitalization of Exagen Inc is 109.12M.
Is Exagen Inc (XGN) currently rated as Buy, Hold, or Sell?
According to analysts, Exagen Inc (XGN) has an overall rating of Buy, with a price target of 8.57.
What is the Earnings Per Share (EPS TTM) of Exagen Inc (XGN)?
The Earnings Per Share (EPS TTM) of Exagen Inc (XGN) is -0.93.
